RxDoctor Payments Data

Victor Hliebay

Family · Clawson, MINPI 1255947438

Payments from drug & device makers

$4,194in general payments, 2019–2025

Across 205 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Collegium Pharmaceutical, Inc.$731
  • AbbVie$625
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$325
  • Relievant Medsystems, Inc.$216
  • Averitas Pharma Inc.$153
  • plus $474 from 14 others

What the payments were for

  • Food & beverage$4,15299%
  • Education$421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,194 in reported general payments places this provider in the 90th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$132,866
Medicare patients
436
Services billed
1,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate37$15,806
OxycontinOxycodone Hcl49$14,590
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen175$4,129
Oxycodone Hcl143$2,075
Lidocaine18$1,617
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen90$1,358
Pregabalin39$1,211
Gabapentin70$824
Naloxone Hcl15$773
Tramadol Hcl79$571
Diclofenac Sodium23$494
Morphine Sulfate ErMorphine Sulfate19$467
Celecoxib12$338
Tizanidine Hcl20$304
Duloxetine Hcl22$284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$731$15,80637 claims
Hikma Pharmaceuticals USAMorphine Sulfate$42$25413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,657 family providers in Michigan.

Other family in Clawson

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →